#### Challenges of Univariate Proxy Variable Screening in High-Dimensional Propensity Score Analysis - An Argument for Multivariate Approaches Dr. Mohammad Ehsanul Karim MSc, PhD<sup>1,2\*</sup> and Yang Lei<sup>3\*</sup> $^{1*}\mathbf{School}$ of Population and Public Health, University of British Columbia, Vancouver, Canada, V6T 1Z3, BC, 2206 East Mall. <sup>2</sup>St. Paul's Hospital, Vancouver, Canada, V6Z 1Y6, BC, 588 - 1081 Burrard Street. <sup>3</sup>Department of Statistics, University of British Columbia, Vancouver, Canada, V6T 1Z4, BC, Room 3182 Earth Sciences Building, 2207 Main Mall. \*Corresponding author(s). E-mail(s): ehsan.karim@ubc.ca; Abstract Purpose: Methods: Results: Conclusion: Keywords: Machine learning, Propensity score, Deep learning, Causal inference JEL Classification: C18 MSC Classification: 92D30, 62P10 1 Background 2 Methods

Aim:

Data and Simulation

Right Heart Catheterization dataset:

Plasmode simulation: See Table 1 for the description of the scenarios under consideration.

**Table 1**: Simulation Scenarios for plasmode simulation based on the Right Heart Catheterization (RHC) study.

Plasmode Simulation Scenario	Exposure Prevalence	Outcome Prevalence	True Odds Ratio	Sample Size
(i) Frequent Exposure and Outcome (Base)	30%	30%	1	3,500
(ii) Rare Exposure and Frequent Outcome	5%	30%	1	3,500
(iii) Frequent Exposure and Rare Outcome	30%	5%	1	3,500

#### True data generating mechanism used in plasmode simulation:

**Performance measures**: From this simulation, we derived several performance metrics: (1) bias, (2) average model standard error (SE; the average of estimated SEs obtained from a model over repeated samples), (3) empirical SE (the standard deviation of estimated treatment effects across repeated samples), (4) MSE, (5) coverage probability of 95% confidence intervals, (6) bias-eliminated coverage, and (7) Zip plot [1, 2].

#### Estimators under consideration

## 3 Results

055

 $\begin{array}{c} 056 \\ 057 \end{array}$ 

058

 $\begin{array}{c} 068 \\ 069 \end{array}$ 

070

 $\begin{array}{c} 071 \\ 072 \end{array}$ 

073

 $\begin{array}{c} 074 \\ 075 \end{array}$ 

 $076 \\ 077 \\ 078$ 

 $079 \\ 080 \\ 081$ 

 $\begin{array}{c} 082 \\ 083 \end{array}$ 

 $084 \\ 085 \\ 086$ 

 $087 \\ 088 \\ 089$ 

090 091 092

093

 $\begin{array}{c} 094 \\ 095 \end{array}$ 

 $\begin{array}{c} 096 \\ 097 \end{array}$ 

098

 $099 \\ 100 \\ 101 \\ 102$ 

103

107

# 4 Real-world analysis

Computing time:

## 5 Discussion

Contextualizing the literature:

Summary of the simulation findings:

Data analysis findings:

Future Direction:

Conclusion:

## List of abbreviations

- $\frac{104}{105}$  1. MSE Mean Squared Error
- 106 2. SE Standard Error
- 108 3. PS Propensity Score

4. AE - Autoencoders	109
5. DL - Deep Learning	110 111
6. MARS - Multivariate Adaptive Regression Splines	112
	113 114
7. SMD - Standardized Mean Difference	114
8. TMLE - Targeted Maximum Likelihood Estimation	116
9. RHC - Right Heart Catheterization	117 118
10. SUPPORT - Study to Understand Prognoses and Preferences for Outcomes and Risks of	119
Treatments	120
	121 122
Declarations	123
Declarations	124 125
Ethics annual and assessed to mosticinate	126
Ethics approval and consent to participate	127
The analysis conducted on secondary and de-identified data is exempt from research ethics approval	128 129
requirements. Ethics for this study was covered by item 7.10.3 in University of British Columbia's	130 131
Policy #89: Research and Other Studies Involving Human Subjects 19 and Article 2.2 in of the	132
Tri-Council Policy Statement: Ethical Conduct for Research Involving Humans (TCPS2).	133 134
	135
Consent for publication	136 137
•	138
Availability of data and materials	139
	140 141
Competing interests	142
Over the past three years, MEK has received consulting fees from Biogen Inc. for consulting unrelated	$\frac{143}{144}$
to this current work. MEK was previously supported by the Michael Smith Foundation for Health	145
Research Scholar award.	$\frac{146}{147}$
Teodorical Sollokal dward.	148
Funding	149 150
runding	150
	150
This work was supported by MEK's Natural Sciences and Engineering Research Council of Canada	152
	153
This work was supported by MEK's Natural Sciences and Engineering Research Council of Canada (NSERC) Discovery Grants and Discovery Accelerator Supplements.	
(NSERC) Discovery Grants and Discovery Accelerator Supplements.	153 154 155 156
	153 154 155 156 157
(NSERC) Discovery Grants and Discovery Accelerator Supplements.	153 154 155 156
(NSERC) Discovery Grants and Discovery Accelerator Supplements.  Authors' contributions	153 154 155 156 157 158